Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (154)
  2. Journal Article (124)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (294)
  2. Genitourinary Oncology Service (294)
  3. Solid Tumor Oncology Division (294)
  4. Weinberg Fellows (108)
  5. Human Oncology and Pathogenesis Program (106)
  6. Surgery (106)

More Groups

People
  1. Robert Motzer (178)
  2. Abraham Hakimi (97)
  3. Darren Feldman (81)
  4. Chung-Han Lee (75)
  5. Maria Carlo (68)
  6. Ritesh Kotecha (65)

More People

Years
  1. 2025 (12)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (120)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (124)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (19)
  6. Biomed Central Ltd (15)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • LITESPARK-012: Pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
    Review

    Choueiri, T. K.; Powles, T.; Voss, M. H.; Plimack, E. R.; Gurney, H.; Song, Y.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Functional and translational consequences of immunometabolic coevolution in ccRCC
    Meeting Abstract

    Reznik, E.; Tang, C.; Xie, A.; Liu, E. M.; Kuo, F.; Kim, M.; Golkaram, M.; Chen, Y.; Gupta, S.; Motzer, R.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Guercio, B. J.; Ratna, N.; Gavrilov, D.; Duzgol, C.; Akhlaq, M.; Teo, M. Y.; Regazzi, A. M.; Kotecha, R. R.; Funt, S. A.; Aggen, D. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types
    Meeting Abstract

    Carlo, M. I.; Schroeder, A.; Mukherjee, S.; Kemel, Y.; Kotecha, R. R.; Lee, C. H.; Shah, N. J.; Feldman, D. R.; Liu, Y. L.; Walsh, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Beckermann, K.; Campbell, M. T.; Haas, N. B.; Ornstein, M. C.; Gao, X.; Mao, S. S.; Hammers, H. J.; George, S.; Nelson, A. A.; Gourdin, T. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma
    Meeting Abstract

    Fitzgerald, K. N.; Kotecha, R. R.; Knezevic, A.; Shapnik, N.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Tomczak, P.; Suáez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Procopio, G.; Mahammedi, H.; Zengerling, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
    Journal Article

    Tang, C.; Xie, A. X.; Liu, E. M.; Kuo, F.; Kim, M.; DiNatale, R. G.; Golkaram, M.; Chen, Y. B.; Gupta, S.; Motzer, R. J.; more...
    Cell Metabolism (2023)

    Fulltext@MSK | Save
  • Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial
    Journal Article

    Pal, S. K.; Albiges, L.; Tomczak, P.; Suárez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Mochalova, A.; Procopio, G.; Mahammedi, H.; more...
    Lancet (2023)

    Fulltext@MSK | Save